StockData

HCW Biologics vs Roivant Sciences

HCWB and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCWB and ROIV compare

Roivant Sciences is the larger company, worth 19604 times as much as HCW Biologics ($28.0B against $1.4M).

HCW Biologics grew revenue faster over the last twelve months (700% versus −67.6% for Roivant Sciences).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −3535% at Roivant Sciences.

Roivant Sciences scores higher on the StockData Score (7 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCWBROIV
Size and price
Market cap$1.4M$28.0B
Share price$0.777$38.71
Change, 1 year−95.7%90.8%
Change, 5 years−99.9%453%
Beta (5Y)2.480.42
Employees–721
StockData Score
Total score67 (better)
Valuation score3 (better)0
Growth score2 (better)0
Performance score11
Health score06 (better)
Dividend score00
Valuation
P/S0.2× (better)3712×
P/B0.2× (better)6.6×
FCF yield–−2.9%
Fair value$15.10–
Margin of safety94.9%–
Growth
Revenue growth (TTM)700% (better)−67.6%
Revenue growth, 5Y average−57.9%−19.1% (better)
Profitability
Gross margin96.7%–
Operating margin−115% (better)−7915%
Net margin−83.8% (better)−3535%
FCF margin–−10901%
Return on equity−151%−6.2% (better)
Return on invested capital−70.7% (better)−407%
Financial health
Debt / equity0.88 (better)0.00
Interest coverage−14.0×–
Current ratio0.0616.72 (better)
Altman Z-score−7.2144.02 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.6%78.1%
Held by insiders34.9%13.9%
Insider net buying, 12 months$532K (better)−$798M
Superinvestors holding–1
Short interest, % of float4.1%7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.